Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.
Iksuda’s PermaLink technology can design ADCs insusceptible to drug de-conjugation.
Iksuda Therapeutics is on mission to design and develop more securely conjugated and efficacious antibody-drug conjugates (ADCs) for the treatment of cancers and is taking a liberated approach to using technology.
The UK firm’s story goes back to 2007 when investor IP Group founded a company called Glythera with two platforms...
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.
Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.
The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.
Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.
Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.
